Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Valmori

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2001
A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapyJ S Blanchet, D Valmori, I Dufau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptideM J Pittet, D E Speiser, D Liénard, et al.
Cancer Research|June 30, 2001
Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytesC Pinilla, V Rubio-Godoy, V Dutoit, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2001
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseasesM J Pittet, A Zippelius, D E Speiser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 1998
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analoguesD Valmori, J F Fonteneau, C M Lizana, et al.
The Journal of Experimental Medicine|September 8, 1999
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individualsM J Pittet, D Valmori, P R Dunbar, et al.
The Journal of Experimental Medicine|November 6, 1998
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytesP Romero, P R Dunbar, D Valmori, et al.
Cancer Research|March 31, 2001
Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoiresP Y Dietrich, P R Walker, A L Quiquerez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2001
The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cellsD E Speiser, M Colonna, M Ayyoub, et al.
European Journal of Immunology|February 17, 2001
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cellsD E Speiser, M Migliaccio, M J Pittet, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2001
A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapyJ S Blanchet, D Valmori, I Dufau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2001
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptideM J Pittet, D E Speiser, D Liénard, et al.
Cancer Research|June 30, 2001
Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytesC Pinilla, V Rubio-Godoy, V Dutoit, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 8, 2001
Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseasesM J Pittet, A Zippelius, D E Speiser, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 20, 1998
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analoguesD Valmori, J F Fonteneau, C M Lizana, et al.
The Journal of Experimental Medicine|September 8, 1999
High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individualsM J Pittet, D Valmori, P R Dunbar, et al.
The Journal of Experimental Medicine|November 6, 1998
Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytesP Romero, P R Dunbar, D Valmori, et al.
Cancer Research|March 31, 2001
Melanoma patients respond to a cytotoxic T lymphocyte-defined self-peptide with diverse and nonoverlapping T-cell receptor repertoiresP Y Dietrich, P R Walker, A L Quiquerez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2001
The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cellsD E Speiser, M Colonna, M Ayyoub, et al.
European Journal of Immunology|February 17, 2001
Human CD8(+) T cells expressing HLA-DR and CD28 show telomerase activity and are distinct from cytolytic effector T cellsD E Speiser, M Migliaccio, M J Pittet, et al.
Pageof 5